Imugene Limited

Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.

Last Movement
$0.015 $0.000 0.00%
Data Source:
Last Updated: 19/06/2019 2:17 PM

Latest Media Releases

Imugene announces Updated Phase Ib HER-Vaxx data

04/06/2019 09:27:00

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance…

Latest News